1984 Volume 32 Issue Supplement2 Pages 234-238
TA-058 is a new semisynthetic penicillin for parenteral use and possesses the advantage of broader antibacterial spectrum, higher and longer-lasting concentration in the serum than those of other existing penicillins. Hence, it is expected that TA-058 has a potent antibacterial activity in vivo.
The clinical effectiveness of TA-058 was evaluated in 23 patients which included 10 pneumonia, 1 pulmonary abscess, 3 pyelonephritis, 5 cystitis, 2 cholecystitis, 1 anorectal abscess and 1 lymphadenitis. The drug was administered by intravenous drip infusion at a dose of 2-4g/day.
The effectiveness rate was calculated as 80% in pneumonia, 100% in lung abscess and in pyelonephritis, 80% in cystitis, 100% in cholecystitis, anorectal abscess and lymphadenitis. No adverse reaction was observed.
Therefore, TA-058 was thought to be safe and very useful for clinical use against infectious diseases.
